Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
Trend | Peers | Company |
---|---|---|
Is return on equity increasing? | No | Yes |
Is net profit margin increasing? | No | Yes |
Is asset turnover increasing? | Yes | Yes |
Is equity multiplier increasing? | Yes | Yes |
Competitors Used |
---|
AstraZeneca PLC |
Bayer Aktiengesellschaft |
Johnson & Johnson |
Perrigo Company plc |
Sandoz Group AG |
Return on Equity Benchmarks | ||||||||
Comparable Companies | ||||||||
AZN | 0P6S | 0R34 | 0Y5E | 0SAN | H6D0 | |||
Return On Equity | ||||||||
Latest Twelve Months | 20% | -10% | 29% | -4% | 0% | 9% | ||
Fiscal Year - 1 | 16% | -8% | 18% | 0% | 1% | 6% | ||
Fiscal Year - 2 | 9% | 12% | 22% | -3% | 10% | 5% | ||
Fiscal Year - 3 | 0% | 3% | 26% | -2% | 11% | 5% | ||
Fiscal Year - 4 | 22% | -40% | 24% | 1% | 6% | 4% | ||
Fiscal Year - 5 | 10% | 5% | 25% | 3% | NA | 2% | ||
Average | 13% | -6% | 24% | -1% | 6% | 5% | ||
Median | 13% | -3% | 25% | -1% | 6% | 5% | ||
Benchmarks | Ticker | |||||||
AstraZeneca PLC | LSE:AZN | |||||||
Bayer Aktiengesellschaft | LSE:0P6S | |||||||
Johnson & Johnson | LSE:0R34 | |||||||
Perrigo Company plc | LSE:0Y5E | |||||||
Sandoz Group AG | LSE:0SAN |
Financial Performance | ||||||||
Comparable Companies | ||||||||
(in millions) | AZN | 0P6S | 0R34 | 0Y5E | 0SAN | H6D0 | ||
Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Dec-24 | Dec-24 | ||
Revenues | ||||||||
Latest Twelve Months | 54,982 | 46,579 | 89,331 | 4,335 | 10,384 | 11,233 | ||
Fiscal Year | 54,073 | 46,606 | 88,821 | 4,373 | 10,384 | 11,233 | ||
Fiscal Year - 1 | 45,811 | 47,637 | 85,159 | 4,656 | 9,979 | 11,302 | ||
Fiscal Year - 2 | 44,351 | 50,739 | 79,990 | 4,452 | 9,306 | 10,858 | ||
Fiscal Year - 3 | 37,417 | 44,081 | 78,740 | 4,139 | 9,678 | 9,545 | ||
Fiscal Year - 4 | 26,617 | 41,400 | 82,584 | 4,088 | 9,658 | 9,892 | ||
Fiscal Year - 5 | 24,384 | 43,545 | 82,059 | 3,870 | NA | 8,480 | ||
Net Income | ||||||||
Latest Twelve Months | 7,772 | (3,253) | 21,810 | (165) | 0 | 1,442 | ||
Fiscal Year | 7,035 | (2,552) | 14,066 | (161) | 0 | 1,442 | ||
Fiscal Year - 1 | 5,955 | (2,941) | 13,326 | (4) | 77 | 1,049 | ||
Fiscal Year - 2 | 3,288 | 4,150 | 16,370 | (131) | 848 | 1,060 | ||
Fiscal Year - 3 | 112 | 1,000 | 17,801 | (131) | 908 | 1,390 | ||
Fiscal Year - 4 | 3,196 | (15,569) | 14,714 | 44 | 462 | 1,145 | ||
Fiscal Year - 5 | 1,335 | 2,391 | 15,119 | 159 | NA | 655 | ||
Total Assets | ||||||||
Latest Fiscal Quarter Prior | 102,293 | 119,881 | 171,966 | 10,640 | 19,430 | 34,055 | ||
Latest Fiscal Quarter | 106,253 | 109,183 | 193,671 | 9,760 | 19,907 | 34,315 | ||
Fiscal Year | 104,035 | 110,850 | 180,104 | 9,648 | 19,907 | 34,315 | ||
Fiscal Year - 1 | 101,119 | 116,259 | 167,558 | 10,809 | 19,430 | 34,055 | ||
Fiscal Year - 2 | 96,483 | 124,877 | 187,378 | 11,017 | 17,557 | 34,815 | ||
Fiscal Year - 3 | 105,363 | 120,241 | 182,018 | 10,426 | 17,542 | 34,451 | ||
Fiscal Year - 4 | 66,729 | 116,804 | 174,894 | 11,488 | 17,946 | 34,130 | ||
Fiscal Year - 5 | 61,377 | 126,174 | 157,728 | 11,301 | NA | 35,711 | ||
Fiscal Year - 6 | 60,651 | 126,732 | 152,954 | 10,983 | NA | NA | ||
Common Equity | ||||||||
Latest Fiscal Quarter Prior | 37,445 | 35,605 | 70,020 | 4,687 | 8,645 | 16,606 | ||
Latest Fiscal Quarter | 41,039 | 32,447 | 78,109 | 4,364 | 8,163 | 16,166 | ||
Fiscal Year | 40,786 | 31,908 | 71,490 | 4,319 | 8,163 | 16,166 | ||
Fiscal Year - 1 | 39,143 | 32,927 | 68,774 | 4,768 | 8,645 | 16,606 | ||
Fiscal Year - 2 | 37,037 | 38,773 | 76,804 | 4,842 | 8,748 | 16,331 | ||
Fiscal Year - 3 | 39,268 | 33,020 | 74,023 | 5,152 | 8,153 | 26,355 | ||
Fiscal Year - 4 | 15,622 | 30,523 | 63,278 | 5,655 | 7,715 | 26,112 | ||
Fiscal Year - 5 | 13,127 | 47,253 | 59,471 | 5,804 | NA | 27,321 | ||
Fiscal Year - 6 | 12,468 | 45,977 | 59,752 | 5,668 | NA | NA |